This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Derma Sciences Reports Third Quarter 2012 Financial Results

Financial Results

Net sales for the third quarter of 2012 were $19,649,773, compared with $15,845,934 for the third quarter of 2011, an increase of 24%. This reflects 67% growth in sales of advanced wound care products to $6,829,168 from $4,077,575 in the third quarter of 2011. Third quarter advanced wound care product sales include $1,787,396 from the operations of MedEfficiency, Inc. (MedEfficiency), which the Company acquired during the second quarter of 2012. Excluding sales of MedEfficiency products from both periods, sales of advanced wound care products grew 36%. Sales of traditional wound care products increased 9% to $12,820,605, compared with $11,768,359, driven by higher first-aid product sales and the replenishment of distributor inventories in Canada that were drawn down during the first half of 2012.

Gross profit for the third quarter of 2012 was $6,908,174 or 35.2% of net sales, up from $4,749,619, or 30.0% of net sales, for the third quarter of 2011. The increase in gross margin reflects increased sales of higher-margin advanced wound care products, which accounted for 35% of net sales for the quarter compared with 26% of net sales in the same period last year.

Selling, general and administrative expense for the third quarter of 2012 was $8,058,441, compared with $5,141,548 for the third quarter of 2011. The increase was principally due to higher sales, marketing and administrative expenditures associated with advanced wound care growth initiatives.

Research and development expense for the third quarter of 2012 was $1,923,670, compared with $200,541 in the third quarter of 2011, reflecting expenses associated with preparing for the DSC127 Phase 3 program.

The net loss for the third quarter of 2012 was $3,055,006 or $0.24 per share, compared with a net loss for the third quarter of 2011 of $789,257 or $0.08 per share. Higher compensation and benefit costs, incremental growth-related sales, marketing and administrative costs, and higher research and development expenses were principally responsible for the larger net loss.

3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs